Stephens analyst Scott Fidel raised the firm’s price target on Tenet Healthcare to $60 from $57 and keeps an Equal Weight rating on the shares following the release of Q4 results and issuance of 2023 guidance. Though Tenet acknowledged that the second SCD development transaction is a year behind initial expectations in its earnings ramp, this "already likely seemed clear to the Street based on the past few quarterly updates," the firm said.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on THC:
- Tenet Healthcare sees 2023 adjusted EPS $4.68-$5.85 vs. $7.58 in 2022
- Tenet Healthcare reports Q4 adjusted EPS $1.96 vs. $2.70 a year ago
- Tenet options imply 7.4% move in share price post-earnings
- 3 Stocks to Buy Today, 1/27/2023, According to Top Analysts
- Tenet Healthcare CFO Daniel Cancelmi retiring at year-end